GLPwatch

Management of obesity.

Am J Health Syst Pharm · 2025

Last updated 2026-05-28

Obesity is a long-term condition with serious health risks, and treatment often involves lifestyle changes, medications, or surgery. Newer drugs like semaglutide and tirzepatide can help people lose more than 15% of their starting weight, which is more than older medications. Doctors consider factors like a person’s health conditions and the drug’s side effects when choosing the best treatment. A team of healthcare providers can help create a plan for long-term weight management and health benefits.

AI summary of the abstract below.

JournalAm J Health Syst Pharm, 2025
Citations4
Molecules
Conditions studied Obesity

Abstract

PURPOSE: This review summarizes the comprehensive management of obesity with a focus on the pharmacology, efficacy, and safety of anti-obesity medications. SUMMARY: Obesity is a highly prevalent chronic disease with significant health risks, requiring a multifaceted approach to treatment. While most approved weight loss medications have modest effects, newer medications such as semaglutide and tirzepatide have shown greater than 15% reduction in baseline weight. Optimal selection of therapy requires taking into consideration patient factors, such as comorbidities and goals, and medication-related factors, including weight loss efficacy, contraindications, and improvements in cardiovascular risk. As the availability of anti-obesity medications increases, multidisciplinary care teams will play an important role in selecting optimal strategies for long-term health benefits in individuals with obesity. CONCLUSION: The expanding array of anti-obesity medications provides valuable treatment options alongside lifestyle interventions and surgical approaches for managing obesity and reducing weight-related health risks. As this therapeutic area continues to grow, selecting optimal agents and educating patients on administration, monitoring, and potential adverse effects will be critical for improving overall outcomes.

Verbatim abstract via PubMed 39325384 ↗